RxDoctor Payments Data

Janet Slawinski

Adult Health · Crystal River, FLNPI 1114125101

Payments from drug & device makers

$721in general payments, 2019–2025

Across 35 payments — averaging $20.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$266
  • GSK$82
  • Exact Sciences$70
  • Astellas Pharma US Inc$69
  • Novartis$34
  • Novo Nordisk$33
  • plus $166 from 9 others

What the payments were for

  • Food & beverage$721100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$721 in reported general payments places this provider in the 55th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$194
Medicare patients
12
Services billed
12

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban96$116,464
Trelegy ElliptaFluticasone/Umeclidin/Vilanter83$102,601
OzempicSemaglutide52$65,130
Repatha SureclickEvolocumab41$47,967
FarxigaDapagliflozin Propanediol38$47,336
XareltoRivaroxaban27$37,231
EntrestoSacubitril/Valsartan26$23,214
JanuviaSitagliptin Phosphate17$15,063
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$14,561
LinzessLinaclotide15$12,004
Breo ElliptaFluticasone/Vilanterol14$8,616
Fluticasone-SalmeterolFluticasone Propion/Salmeterol18$5,890
Levothyroxine Sodium539$5,570
Gabapentin190$5,465
Celecoxib60$5,375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$13$116,46496 claims
GSKTrelegy Ellipta, Breo Ellipta$82$111,21797 claims
Novo NordiskOzempic$33$65,13052 claims
NovartisEntresto$34$23,21426 claims
AbbVieLinzess, Synthroid$17$14,78455 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,237 adult health providers in Florida.

Other adult health in Crystal River

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →